NT-125 / AstraZeneca - LARVOL DELTA

Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors (Businesswire) - "Neogene Therapeutics, Inc...announced the approval of the company’s first Clinical Trial Application (CTA) by the Dutch regulatory authority for a Phase 1 study of NT-125, an autologous, fully-individualized, multi-specific TCR therapy for the treatment of advanced solid tumors. The Phase 1 study will enroll adult patients with various types of advanced solid tumors in partnership with the Netherlands Cancer Institute (NKI), an internationally acclaimed research institute and leading cancer clinic."

New P1 trial • Oncology